Intravenous magnesium sulfate

Phase 3

Intravenous magnesium sulfate is one of 3 therapeutic programs targeting Opioid Consumption. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Opioid ConsumptionRecruiting

Opioid ConsumptionPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Opioid Consumption

#DrugCompanyPhaseTrials

Intravenous magnesium sulfate

MMedical University of Warsaw

Phase 3

1 2

Hydrocodone

MM.D. Anderson Cancer Center

Phase 2

1 3

Horizant

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Opioid Consumption

NCT06563349

Clinical

Trials by Indication[1]

Opioid Consumption1 trial

The Effect of Intravenous Magnesium Infusion on the Opioid Consumption, the Circulatory, Metabolic and Hormonal Response to Intubation and Surgical Trauma During Anaesthesia for Laparoscopy in Children. Randomized Clinical Trial.

Recruiting·MMedical University of Warsaw·Approved·NCT06563349·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous magnesium sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous magnesium sulfate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Medical University of Warsaw company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMedical University of Warsaw

Intravenous magnesium sulfate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Opioid Consumption1 trial

References

Drug Info

Quick Facts

Related News